AZD9898（Cat No.:I018084）is an inhaled, selective DP2_2 (CRTH2) receptor antagonist developed to target inflammatory pathways in respiratory diseases. By blocking prostaglandin D2_2-mediated signaling, it reduces activation and migration of eosinophils, basophils, and Th2 lymphocytes, key drivers of airway inflammation. Designed for local delivery to the lungs, AZD9898 minimizes systemic exposure while enhancing therapeutic efficacy. It has been investigated in asthma and other allergic airway disorders as a potential treatment to improve lung function, decrease inflammation, and provide better control of symptoms in patients with Th2-driven disease.